Last edition
News about Global Pharma
ORIC Pharmaceuticals Signs Clinical Supply Deal with Janssen Research and Development
Under the terms of the agreement, ORIC® will conduct and sponsor the trial and Johnson & Johnson will provide SC amivantamab.
Global Pharma | 15/01/2025 | By Aishwarya | 403
PAG Acquires Majority Stake in Pravesha Industries to Boost Pharma Packaging Footprint
Pravesha produces more than 15,000 metric tons of plastic bottles, closures, and drums and more than two billion units of cartons, labels, and leaflets annually for some of the world’s largest pharmaceutical companies. <br />
Global Pharma | 15/01/2025 | By Abha | 707
AbbVie and REGENXBIO Update on ABBV-RGX-314 Clinical Program
AbbVie and REGENXBIO will plan a Phase 3 clinical program. The clinical program will utilize the in-office SCS Microinjector® to deliver gene therapy to the suprachoroidal space of the eye.
Global Pharma | 15/01/2025 | By Aishwarya | 441
Vascarta Partners with CUNY to Enhance Chemotherapy Efficacy and Safety
Vascarta has secured exclusive rights to a novel linker chemistry developed by the City College of New York (CUNY) for creating cancer therapies that enhance efficacy and reduce side effects by linking chemotherapeutic agents with curcumin.
Global Pharma | 14/01/2025 | By Manvi | 124
FDA Accepts Biologics License Application for Leqembi Subcutaneous Autoinjector
BioArctic AB announced that the FDA has accepted its partner Eisai's Biologics License Application for Leqembi's subcutaneous autoinjector, potentially enabling at-home maintenance dosing for early-stage Alzheimer's disease.
Global Pharma | 14/01/2025 | By Manvi | 350
Cycle Pharma Acquires Banner Life Sciences
BAFIERTAM will become Cycle’s second branded product for the treatment of MS alongside TASCENSO ODT® (fingolimod).
Global Pharma | 14/01/2025 | By Aishwarya | 894
Salarius Pharmaceuticals Signs Definitive Merger Agreement with Decoy Therapeutics
Decoy’s product pipeline targets unmet needs in respiratory infectious diseases and gastroenterology (GI) oncology indications.
Global Pharma | 14/01/2025 | By Aishwarya | 337
In a groundbreaking clinical study, Zaynich (Zidebactam/Cefepime, WCK 5222) showcased over 97 percent clinical efficacy in treating critically ill patients with carbapenem-resistant Gram-negative infections.
Global Pharma | 13/01/2025 | By Manvi | 541
Telix Pharmaceuticals has regained marketing and distribution rights for Scintimun from Curium Pharma, with a strategic agreement appointing Curium as its manufacturer.
Global Pharma | 13/01/2025 | By Manvi | 500
Synaffix Signs License Deal with Mitsubishi Tanabe Pharma for ADC Technology
Synaffix is responsible for the manufacturing of the components that are related to its proprietary technologies, and MTPC is responsible for the research, development, manufacturing and commercialization of the ADC.
Global Pharma | 13/01/2025 | By Aishwarya | 284
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy